ArticleThe oncologist2021

RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.

Alexa B Schrock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.